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Genetic variants in SLC16A11 were recently reported to
be associated with type 2 diabetes in Mexican and other
Latin American populations. The diabetes risk haplotype
had a frequency of 50% in Native Americans from Mexico
but was rare in Europeans and Africans. In the current
study, we analyzed SLC16A11 in 12,811 North American
Indians and found that the diabetes risk haplotype,
tagged by the rs75493593 A allele, was nominally associated with type 2 diabetes (P = 0.001, odds ratio 1.11).
However, there was a strong interaction with BMI (P = 5.1 3
1027) such that the diabetes association was stronger in
leaner individuals. rs75493593 was also strongly associated with BMI in individuals with type 2 diabetes (P = 3.4 3
10215) but not in individuals without diabetes (P = 0.77).
Longitudinal analyses suggest that this is due, in part, to
an association of the A allele with greater weight loss
following diabetes onset (P = 0.02). Analyses of global
gene expression data from adipose tissue, skeletal muscle,
and whole blood provide evidence that rs75493593 is associated with expression of the nearby RNASEK gene,
suggesting that RNASEK expression may mediate the
effect of genotype on diabetes.

The Slim Initiative in Genomic Medicine for the Americas
(SIGMA) Type 2 Diabetes Consortium recently reported a
haplotype consisting of ﬁve common exonic variants,
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including rs75493593, in the monocarboxylic acid transporter gene SLC16A11 that was strongly associated with
type 2 diabetes in Mexican and other Latin American
populations (1). The diabetes risk haplotype had a frequency of 50% in Native Americans from Mexico but was
rare in Europeans and Africans (1), suggesting it may
contribute to the higher burden of type 2 diabetes among
American Indians. Our previous study of 63 established
type 2 diabetes variants in 3,421 individuals from a longitudinal diabetes study in a Southwestern American Indian
(SWAI) population showed little evidence of association
between rs75493593 and type 2 diabetes (2). To further
assess whether SLC16A11 variants are associated with type 2
diabetes in American Indians, we expanded our analysis
by genotyping three tag single nucleotide polymorphisms
(SNPs) (rs75493593, rs148775056, and rs9303212) that
capture all variants with a frequency .0.01 across the
SLC16A11 locus in our population-based SWAI sample
(N = 7,295). As one of the tag SNPs, rs75493593, captures
the previously reported Mexican diabetes risk haplotype, it
was further analyzed in two additional samples of American Indians from the Phoenix extension of the Family
Investigation of Nephropathy and Diabetes (FIND) (N =
3,095) and the Strong Heart Study (SHS) (N = 2,421) for a
combined total of 12,811 North American Indians. As the
SIGMA study found that the SLC16A11 diabetes risk
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alleles were associated with leaner BMI in individuals with
diabetes, we also examined whether SLC16A11 genotypes
interact with BMI in their association with diabetes. To
date, none of the SLC16A11 missense variants have been
shown to alter protein function; therefore, we merged
rs75493593 genotypic data with gene expression data to
search for potential expression quantitative loci (eQTLs)
that could provide an alternative mechanism affecting the
risk for type 2 diabetes.
RESEARCH DESIGN AND METHODS
Participants for the Type 2 Diabetes and BMI Analyses

SWAI

From 1965–2007, SWAIs from a community in Arizona
participated in biennial health exams that included a 75-g
oral glucose tolerance test (OGTT), measures of height
and weight to calculate BMI, and a blood draw for DNA
isolation (3). Diabetes status was determined according to
the 1997 criteria of the American Diabetes Association
(fasting plasma glucose $7.0 mmol/L or 2-h plasma glucose
$11.1 mmol/L) (4) or from a previous clinical diagnosis.
Fasting glucose, 2-h glucose, and insulin concentrations
were analyzed using data from the participant’s last nondiabetic exam. Estimates of insulin resistance (HOMA-IR)
and b-cell function (HOMA-B) were calculated using the
homeostatic model (5). The current study includes all
individuals (N = 7,710) for whom diabetes status is recorded
and DNA is currently available.
FIND

Participants from the Phoenix extension of FIND, a
multicenter study designed to identify genes involved in
diabetic nephropathy (6), were required to be of $50%
American Indian heritage (self-reported) and most were
urban-dwelling American Indians living near Phoenix, AZ.
Individuals were examined once and diabetes status
was determined by 2010 American Diabetes Association
criteria based on fasting blood glucose concentrations
($7.0 mmol/L) or HbA1c ($6.5%) (7) or from a prior
clinical diagnosis (6). The current study includes all participants (N = 3,106) who were not also studied as part of
the SWAI sample.
SHS

Participants are American Indians who underwent health
exams at study sites located in Arizona, North and South
Dakota, and Oklahoma (8). Diabetes status was determined
by 1998 World Health Organization criteria based on
2-h blood glucose $11.1 mmol/L, fasting blood glucose
$7.0 mmol/L, current use of diabetes medication, and/or
if an individual was previously diagnosed with diabetes (9).
The current study includes all participants (N = 2,451) who
were not also studied as part of the SWAI sample.
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Participants for the Inpatient Metabolic Studies

Some individuals (N = 561, age 18–45 years) from the
SWAI sample also participated in inpatient metabolic exams
in our Clinical Research Center. These individuals did not
have diabetes, as determined by a 75-g OGTT; were healthy
based on medical history, physical examination, and routine laboratory tests; and were not taking any medications.
The OGTT was performed after an overnight fast and
blood was drawn before and at 30, 60, 120, and 180 min
after glucose ingestion for determining plasma glucose
and insulin concentrations. Insulin action was assessed
using the two-step hyperinsulinemic-euglycemic clamp
technique to measure insulin-stimulated glucose disappearance (uptake) rates (10). To determine acute insulin
response, a 25-g bolus of glucose was injected intravenously over 3 min and blood samples were collected before infusion and at 3, 4, and 5 min after the injection to
determine plasma glucose and insulin concentrations. Acute
insulin response was calculated as one-half the mean increment in plasma insulin concentrations from 3 to 5 min
(10). Percent body fat was estimated by underwater weighing or by total body dual energy X-ray absorptiometry
(DPX-1; Lunar Radiation, Madison, WI) (11). A subset of
the inpatient subjects (N = 423) also participated in our
metabolic chamber studies to determine energy expenditure and substrate (carbohydrate, lipid, and protein) oxidation in the metabolic respiratory chamber (12).
Genotyping

Genotyping was done by allelic discrimination using TaqMan
genotyping assays (Applied Biosystems, Foster City, CA).
All genotypic data included in the analyses met our qualitycontrol criteria, which requires a successful call rate of
$95%, a lack of deviation from Hardy-Weinberg equilibrium
at P , 0.001, and a discrepancy rate of #1% in masked
duplicates (430, 120, and 88 blind duplicates for the SWAI,
FIND, and SHS samples, respectively).
Statistical Analyses

The association between genotypes and type 2 diabetes
was determined with logistic regression modeling (additive model), where homozygotes for the major allele (A1/
A1), heterozygotes (A1/A2), and homozygotes for the
minor allele (A2/A2) were coded to a numeric variable for
genotype (0, 1, and 2). In individuals from the SWAI and
SHS community-based studies, the model was ﬁt with the
generalized estimating procedure to account for sibship.
For the FIND sample, the genomic control procedure (13)
was used to account for unspeciﬁed relationships based
on 42 random markers from throughout the genome. Individual estimates of European admixture, which were
used as covariates in analyses, were derived from 45
markers with large differences in allele frequency between
populations (14) with the method of Hanis et al. (15). A
meta-analysis for the SWAI, FIND, and SHS samples was
conducted by the inverse variance method (16). Heterogeneity among the samples was quantiﬁed by the I2 measure
and statistical signiﬁcance was tested by Cochran Q statistic
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Brief descriptions of the study cohorts are provided below
and their clinical characteristics are shown in Supplementary Table 1. Each study was approved by an institutional
review board and participants gave informed consent.
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Gene Expression and Mediation Analyses

Genome-wide mRNA levels had previously been measured
using the Affymetrix 1.0 Human Exon microarray in
adipose tissue (N = 187) and skeletal muscle (N = 196)
biopsies from a subset of the SWAI sample (all were without diabetes) (18). Genome-wide mRNA levels in whole
blood were also available from a prior study in a subset of
the FIND sample (N = 1,412, 23% with diabetes) who had
been genotyped for 42 established type 2 diabetes–
susceptibility variants including rs75493593. Whole-blood
gene expression levels were measured using the Illumina
HumanHT-12 v4 Expression BeadChip. A x2 tail test was
used to assess associations between genotype and 15,854
transcripts expressed above background (19) that mapped
to unique locations and that were free of variants located
in probe set binding sites according to ReMOAT annotation (20). For variants associated with both type 2 diabetes (P , 0.05) and whole-blood transcript levels (P ,
0.005), a formal mediation analysis was used to quantify
the extent to which the pattern of associations was consistent with an effect on transcript that mediates the
variant-diabetes association. Signiﬁcance of mediation
was assessed by the Sobel test (21), and the percentage
of the variant effect on diabetes that was potentially mediated by the transcript was calculated (22). Additional
details are described in the Supplementary Data online.

As associations between SLC16A11 variants and type 2
diabetes have previously been established in other populations, we considered a P , 0.05 as statistically signiﬁcant for variant-diabetes–related phenotype associations.
In the whole transcriptome analyses, which lack a speciﬁc
a priori hypothesis, we calculated the false discovery rate
(23) to account for multiple comparisons.
RESULTS
Association Analysis of Type 2 Diabetes Using
Cross-sectional Data

Previously analyzed whole-genome sequence data (403
coverage) from 296 SWAI individuals were used to identify
14 variants with a minor allele frequency $0.01 in the
genomic region spanning the SLC16A11 locus (Supplementary Fig. 1A). Linkage disequilibrium (LD) information
(r2 $0.85) for the 14 variants could be captured by genotyping three tag SNPs, rs75493593, rs148775056, and
rs9303212 (Supplementary Fig. 1B). Most of the common
variants, including all ﬁve exonic variants that make up
the previously reported type 2 diabetes risk haplotype in
the SIGMA study, fell into one major LD group tagged by
rs75493593. The three tag SNPs were genotyped in our
population-based SWAI sample (N = 7,295), but none were
associated with type 2 diabetes (Supplementary Table 2).
As rs75493593 tagged the diabetes risk haplotype reported
in the SIGMA study, this variant was further genotyped in
two additional samples of American Indians from the FIND
(N = 3,095) and SHS (N = 2,421) studies. Meta-analysis of
the three samples (N = 12,811) detected a nominal association between the rs75493593 A allele and higher risk of
type 2 diabetes (P = 0.001, odds ratio [OR] 1.11 [95% CI
1.04–1.19]) (Table 1), which is directionally consistent with
the Mexican study.
Analyses of rs75493593 Genotype by BMI and Type 2
Diabetes Interactions

A signiﬁcant genotype 3 BMI interaction was observed
for the association of rs75493593 with type 2 diabetes
(combined American Indian sample, Pinteraction = 5.1 3 1027)

Table 1—Diabetes association results for rs75493593 in the American Indian samples
Genotype N for subjects
with diabetes
Subjects*

Genotype N for subjects
without diabetes
P‡

OR (95% CI)§||

736

0.38

1.04 (0.95–1.14)

430

0.008

1.27 (1.10–1.45)

Allele A† frequency

CC

CA

AA

CC

CA

AA

SWAI

0.39

840

1,142

406

1,879

2,292

FIND

0.44

265

392

209

763

1,036

SHS

0.40

369

490

202

566

618

176

0.04

1.15 (1.01–1.30)

Combined

0.41

1,474

2,024

817

3,208

3,946

1,342

0.001

1.11 (1.04–1.19)

*Combined = SWAI + FIND + SHS subjects. †The A allele for rs75493593 is the diabetes risk allele in the Mexican (SIGMA) study.
‡P value for the SWAI sample was adjusted for age, sex, birth year, admixture estimate, and American Indian heritage. P value for
the FIND sample was adjusted for age, sex, admixture estimate, and tribal membership; the P value was then adjusted by genomic
control to account for any relatedness or population stratiﬁcation. P value for the SHS sample was adjusted for age, sex, admixture
estimate, and study center. P value for the combined analysis was adjusted for age, sex, and study center. §ORs for rs75493593 are
given per copy of the A allele. ||The proportion of variance (I2) in the effect estimates attributable to heterogeneity between the three
populations was 65% (P = 0.06).
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(17). For longitudinal analyses of diabetes, SWAI individuals who did not initially have diabetes were followed
from their ﬁrst examination after age 15 years until development of diabetes or until their last examination. Cox
proportional hazards regression was used to estimate the
risk (hazard ratio [HR]) of developing type 2 diabetes. A
similar analysis was performed for the SHS using data
from phases I through III. Linear regression was used to
analyze the associations between genotype and continuous variables, and the models were ﬁt with the generalized estimating equation procedure to account for sibship.
Statistical analyses were performed using the statistical
analysis system of the SAS Institute (Cary, NC).
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Figure 1—ORs for the associations between rs75493593 and type
2 diabetes when the subjects are stratiﬁed by BMI (kg/m2). P values
for the SWAI sample were adjusted for age, sex, birth year, admixture
estimate, and American Indian heritage. P values for the FIND sample
were adjusted for age, sex, admixture estimate, and tribal membership;
the P values were then adjusted by genomic control to account for any
relatedness or population stratiﬁcation. P values for the SHS sample
were adjusted for age, sex, admixture estimate, and study center. ORs
are given per copy of the A allele. Error bars indicate 95% CI. P values
for BMI by genotype interaction on the risk of having diabetes are P =
5.5 3 1026 (SWAI), P = 0.04 (FIND), P = 0.19 (SHS), and P = 5.1 3 1027
(Combined). Combined, SWAI, FIND, and SHS populations.
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Table 4. The association between the risk haplotype and
lower BMI in individuals with diabetes was also observed in
the Mexican study (P = 5.2 3 1024) (1); in combination with
the present data, rs75493593 is a replicated variant for BMI
at genome-wide statistical signiﬁcance in individuals with
diabetes (combined Mexican and American Indian sample,
P = 5.2 3 10216).
Longitudinal Analysis of Diabetes Risk as a Function of
rs75493593

To assess whether individuals with the rs75493593 A
allele develop diabetes at a leaner BMI or lose more
weight after diabetes onset, 4,088 SWAI and 1,073 SHS
individuals who did not have diabetes at their ﬁrst exam
and had longitudinal follow-up data were analyzed. Among
the SWAI individuals (mean age 22.0 years), 1,498 (37%)
developed diabetes during a mean follow-up time of
13.5 years; for the SHS participants (mean age 55.1 years),
222 (21%) developed diabetes during a mean follow-up of
6.6 years. A proportional hazards regression analysis (HR)
showed that rs75493593 did not predict type 2 diabetes
in either sample (SWAI, HR 1.04 [95% CI 0.97–1.12], P =
0.31; SHS, 1.00 [0.81–1.23], P = 0.97) or when the SWAI
and SHS samples were combined (1.03 [0.97–1.11], P =
0.35). However, when grouped by BMI, a nominally signiﬁcant HR was detected for SWAI individuals with a BMI
,25 kg/m2 (1.18 [1.01–1.38], P = 0.03) (Fig. 2), where
the rs75493593 A allele was associated with increased risk
of diabetes, a ﬁnding consistent with the cross-sectional
analyses. The HR for rs75493593 was similarly elevated in
the SHS individuals with BMI ,25 kg/m2, and the association was nominally signiﬁcant in the combined sample
(1.20 [1.03–1.39], P = 0.02) (Fig. 2). However, a signiﬁcant
rs75493593 genotype 3 baseline BMI interaction was not
observed in the SWAI, SHS, or combined samples
(Pinteraction = 0.94, 0.08, and 0.57, respectively) (Fig. 2).
The longitudinal relationship with change in BMI, as measured by the slope, across nondiabetic exams and across
exams conducted after diabetes onset was also analyzed.
When SWAI participants did not have diabetes, there was
no difference in BMI change by genotype (N = 4,480, P =
0.32) (Fig. 3A). In contrast, after type 2 diabetes onset,
there was an association between rs75493593 and BMI
slope (N = 1,632, P = 0.02) (Fig. 3A), where the A allele
was associated with increased weight loss. The decrease in
BMI after diabetes onset was 1.2% versus 0.5% per year
for individuals homozygous for the A and C alleles, respectively. There were no signiﬁcant associations between
rs75493593 and weight change in the SHS individuals,
although it should be noted that the weight changes in
this older population were smaller in magnitude (Fig. 3B).
Association Analysis of Quantitative Type 2 Diabetes–
Related Traits

To evaluate the physiology underlying the associations
with type 2 diabetes, glucose and insulin concentrations
along with HOMA measures of insulin secretion and resistance were analyzed in SWAI individuals who had
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(Fig. 1 and Supplementary Table 3). After stratifying the
individuals into BMI categories, a modest association was
observed between rs75493593 and diabetes for the nonobese groups (in the combined American Indian sample,
P = 4.9 3 1023 and 7.5 3 1026 for the BMI categories
,25 and 25–30 kg/m2, respectively), where the A allele
was associated with increased risk for diabetes (OR 1.41
and 1.36, respectively), but among the heavier individuals
(BMI 35–40 and .40 kg/m2), the A allele was associated
with decreased risk for diabetes (OR 0.88 and 0.84, respectively). Similar trends were observed in each American Indian sample when analyzed separately (Fig. 1 and
Supplementary Table 3). This same phenomenon is reﬂected
in a strong diabetes 3 genotype interaction for the association of rs75493593 with BMI (in the combined American
Indian sample, Pinteraction = 3.4 3 10210) (Table 2). Although
an association between rs75493593 and BMI in the combined sample was observed (6.4 3 1025), where individuals
with diabetes who carry the risk A allele have lower BMIs,
this association was due entirely to individuals with type 2
diabetes (with diabetes, P = 3.4 3 10215; without diabetes,
P = 0.77) (Table 2). The distribution of genotype across BMI
categories and diabetes status is given in Supplementary
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2,411

11,768

SHS
All
With diabetes
Without diabetes

Combined
All
With diabetes
Without diabetes

0.02

0.23

3.4 3 10210

20.031

20.013

20.037
4,255
1,435
2,820

933
367
566

1,027
265
762

2,295
803
1,492

CC

5,482
1,974
3,508

1,101
484
617

1,423
391
1,032

2,958
1,099
1,859

CA

Genotype N

2,031
799
1,232

377
202
175

638
209
429

1,016
388
628

AA

33.0 6 8.1
35.4 6 8.1
31.7 6 7.8

30.5 6 6.1
32.5 6 6.4
29.2 6 5.6

31.7 6 7.6
35.2 6 7.2
30.4 6 7.3

34.5 6 8.7
36.9 6 8.7
33.3 6 8.4

CC

33.0 6 8.0
34.5 6 8.2
32.2 6 7.8

30.7 6 6.2
32.2 6 6.7
29.4 6 5.6

31.5 6 7.2
34.4 6 7.8
30.4 6 6.7

34.7 6 8.6
35.5 6 8.8
34.2 6 8.5

CA

Mean BMI 6 SD
B
20.018
20.051
0.001
20.0007
20.029
0.004
20.012
20.02
20.012
20.012
20.037
20.001

AA
33.6 6 7.8
33.3 6 8.0
33.7 6 7.7
31.1 6 7.0
33.3 6 7.3
30.1 6 6.6
30.1 6 5.7
31.0 6 5.7
29.1 6 5.6
32.2 6 7.4
32.7 6 7.4
31.8 6 7.3

BMI association based on diabetes status

6.4 3 1025
3.4 3 10215
0.77

0.03
0.01
0.13

0.91
5.5 3 1023
0.55

5.0 3 1025
4.2 3 10214
0.84

P†

SLC16A11 and Type 2 Diabetes in American Indians
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*Combined = SWAI + FIND + SHS subjects. †P values for the SWAI sample were adjusted for age, sex, birth year, admixture estimate, and American Indian heritage. P values for the
FIND sample were adjusted for age, sex, admixture estimate, and tribal membership; the P values were then adjusted by genomic control to account for any relatedness or population
stratiﬁcation. P values for the SHS sample were adjusted for age, sex, admixture estimate, and study center.

3,088

FIND
All
With diabetes
Without diabetes

1.1 3 10

210

Pinteraction†

20.054

B

Genotype 3 diabetes interaction

6,269

N

SWAI
All
With diabetes
Without diabetes

Subjects*

Table 2—BMI association results for rs75493593 in the American Indian samples
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available data from their last nondiabetic exam (N ;5,200).
Nominal evidence for a rs75493593 genotype 3 BMI interaction was detected for various traits including fasting
insulin, HOMA-IR, and HOMA-B (Pinteraction = 0.03–0.04,
Supplementary Table 5); however, these associations are
too weak to be conclusive of the underlying physiology. In
a subset of SWAI individuals without diabetes who had
undergone metabolic testing in our Clinical Research Center,
there was a nominal but consistent association between
rs75493593 and basal carbohydrate and lipid oxidation
when measured during a hyperinsulinemic-euglycemic
clamp (N = 521) and when measured in a human respiratory chamber (N = 423) (Supplementary Table 6). Individuals homozygous for the A allele had higher mean
carbohydrate oxidation rates and lower mean lipid oxidation rates compared with the other two genotypes (P =
0.007 and 0.006, respectively) (Fig. 4A and B), resulting
in a slightly higher mean 24-h respiratory quotient (P =
0.01). These associations, although weak, are consistent
between two independent in vivo measures of carbohydrate and lipid oxidation.
Analysis of rs75493593 as an eQTL

On the basis of SIFT prediction, only one of the four
SLC16A11 missense variants, rs13342692 (D127G), is
predicted to be damaging with a SIFT score of 0.05 (Supplementary Table 7), just reaching the cutoff for deleterious amino acid substitutions (SIFT score thresholds:
tolerated .0.05, damaging #0.05 [24]). To search for

Figure 3—Longitudinal BMI pattern in SWAI and SHS individuals
without diabetes and after diabetes onset for rs75493593. The longitudinal relationship with change in BMI for the SWAI (A) and SHS
(B) individuals. P value for those without diabetes was adjusted for
sex, birth year, baseline age, and American Indian heritage. P value
for after diabetes onset was adjusted for sex, birth year, diabetes
duration, and American Indian heritage.

additional mechanisms whereby these variants could
have a functional effect, genotypic data for rs75493593
were merged with previously measured global adipose tissue
(N = 187) and skeletal muscle (N = 196) gene expression
data to determine whether variants tagged by rs75493593
could function as an eQTL. The genome-wide eQTL analyses
identiﬁed RNASEK, which is located approximately 27 kb
upstream of rs75493593 (SLC16A11), as one of the top
eQTL genes in both tissues that were biopsied from different SWAI individuals (adipose tissue P = 2.1 3 1024 and
skeletal muscle 1.7 3 1028) (Table 3). The microarray mean
RNASEK expression levels based on rs75493593 genotypes
are shown in Fig. 5A and B. The association between
rs75493593 and adipose tissue RNASEK expression was replicated by quantitative RT-PCR (N = 182, P = 8.0 3 1024)
(Fig. 5C). There were no microarray expression data for
SLC16A11 in either adipose tissue or skeletal muscle;
however, directly measuring SLC16A11 mRNA levels by
quantitative RT-PCR showed no association between
rs75493593 and expression in adipose tissue (N = 182,
P = 0.30, data not shown). The association between
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Figure 2—Longitudinal analysis of diabetes risk as a function of
rs75493593 and obesity status. HRs for the SWAI, SHS, and combined samples after stratifying by BMI (kg/m2). P values were
adjusted for baseline BMI, baseline age, birth year, admixture
estimate, and American Indian heritage. HRs and 95% CIs (error
bars) were estimated using the Cox proportional hazards model.
Pinteraction is the P value for BMI by rs75493593 genotype interaction
on the risk of developing diabetes. Combined, SWAI, FIND, and
SHS populations. Statistically signiﬁcant data appear in boldface.
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7.7 3 1025
2099580
Transcript cluster start and stop locations are from build 37. Chr, chromosome.

2
FHL2

2568687

105969445

106134573

1.7 3 10

C19orf36

19

3816225

2084101

4.1 3 1024
130462583
L3MBTL3

23

17
TMEM92

3726298

48306764

48358846

1.5 3 1023

6

2925510

130339608

3.9 3 1024
132430421
3
CCRL2

4047185

46442652

46454468

1.4 3 10

PUS1

12

3438581

132413765

2.9 3 1024
1859457
C1orf222
12
KCNA6

3401953

4918308

4923944

1.4 3 10

23

1

4053322

1853396

2.7 3 1024
17571725
19
NXNL1
1.4 3 1023
1959931
1940940
11
TNNT3

3317117

23

3854477

17547267

2.6 3 1024
73937249
10
DUPD1

3295235

76796453

76833383

1.2 3 10

ENC1

5

2862696

73923235

1.3 3 1024
68255892
ARFGEF1
7
RSPH10B

3037100

5965177

6010420

9.9 3 10

23

8

3139035

68087455

8.6 3 1025
73119282
2
SPR

24

9.0 3 1024
1926239
1858178
20
SIRPA

3873629

2.1 3 10
6917837
6915756
17
RNASEK

3708186

2488584

73114532

1.7 3 1025
160119332
160061138
IGSF8

1

2439975

6917837
6915756
17
RNASEK
5
FAM53C

2830698

137673257

137685632

7.7 3 10

25

P
Transcript
cluster stop
Transcript
cluster start
Transcript
cluster ID
Chr
eQTL
gene

24

3708186

Transcript
cluster stop
Transcript
cluster start
eQTL
gene

Chr

Transcript
cluster ID

Skeletal muscle
Adipose tissue

Table 3—Top 10 eQTL genes for rs75493593 in adipose tissue and skeletal muscle

rs75493593 and RNASEK expression was further analyzed
in whole blood from a subset of the FIND sample (N =
1,412, 23% with diabetes) for whom both genome-wide
expression data and genotyping data for 42 established
type 2 diabetes variants, including rs75493593, were available. In these individuals, the rs75493593 A allele was also
associated with lower RNASEK expression in whole blood
(P = 1.6 3 1025) (Fig. 5D) and increased risk for diabetes
(P = 3.0 3 1023, OR 1.36) (Fig. 5E); lower RNASEK expression was associated with an 18% increase per standard
deviation in the odds of type 2 diabetes (P = 6.0 3 1023,
OR 0.82) (Fig. 5F). To examine the extent to which the
rs75493593-RNASEK eQTL could account for the association
between genotype and diabetes, a formal mediation analysis
was conducted and signiﬁcant mediation was observed (P =
0.01). To compare this mediation effect with the potential
effect of other type 2 diabetes susceptibility variants in a
transcriptomic context, the remaining 41 established type 2
diabetes variants genotyped in the 1,412 FIND participants
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Figure 4—Association analyses for rs75493593 and carbohydrate
and lipid oxidation. A: Association between rs75493593 and carbohydrate intake, carbohydrate oxidation, and carbohydrate balance.
B: Association between rs75493593 and lipid intake, lipid oxidation,
and lipid balance. Genotype N = CC, 145; CA, 179; AA, 66. P values
for carbohydrate and lipid intake and carbohydrate and lipid balance were adjusted for age, sex, percent body fat, family membership, and American Indian heritage. P values for carbohydrate and
lipid oxidation were adjusted for age, sex, percent body fat, family
membership, American Indian heritage, and energy balance.

1.7 3 1028
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were also analyzed. Six of the 41 variants were associated
with type 2 diabetes (P , 0.05, data not shown), and these
6 variants along with rs75493593 gave rise to 85 potential
eQTL genes (P , 0.005 for association between variant and
transcript levels) (Supplementary Table 8). Only 3 additional
eQTLs displayed statistically signiﬁcant (P , 0.05) mediation,
and none of the 3 displayed a stronger mediation effect than
the rs75493593-RNASEK eQTL (Supplementary Table 9).
DISCUSSION

In the SIGMA study, it was noted that among all
individuals with type 2 diabetes, those who carry the

risk haplotype had lower BMIs than those who do not
carry the risk haplotype, suggesting that diabetes onset
occurred at a lower BMI among carriers (1). Our study of
American Indians identiﬁed a signiﬁcant rs75493593
genotype 3 BMI interaction where individuals with
a BMI ,35 kg/m2 who carry the diabetes risk A allele were
at increased risk for type 2 diabetes and individuals with
higher BMIs who carry the A allele were protected from
diabetes. Consistent with the cross-sectional results, for
the SWAI and SHS individuals with longitudinal data on
BMI and diabetes status, we observed that HRs for type
2 diabetes by genotype were higher in the leanest BMI
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Figure 5—rs75493593-RNASEK eQTL results for the SWAI and FIND subjects, and diabetes prevalence based on rs75493593 genotypes
and RNASEK expression for the FIND subjects. A: Exon microarray mean RNASEK expression levels based on rs75493593 genotypes for
adipose tissue. B: Exon microarray mean RNASEK expression levels based on rs75493593 genotypes for skeletal muscle. C: RT-PCR
association results for rs75493593 and mean RNASEK gene expression in adipose tissue. RT-PCR assays were done using the standard
curve method. RNASEK mRNA expression levels were normalized with b-actin. P values were adjusted for age, sex, and American Indian
heritage. D: Mean RNASEK expression in whole blood based on rs75493593 genotype. b is the mean difference in RNASEK expression
and is shown in SD units per copy of the A allele. P value is adjusted for age, sex, and American Indian heritage. E: Diabetes prevalence
based on rs75493593 genotype for the 1,412 American Indians from the FIND study. OR is expressed per copy of the A allele. P value is
adjusted for age, sex, and American Indian heritage. F: Diabetes prevalence based on RNASEK expression quartiles. N ;353 for each
quartile. OR is expressed per SD of expression. P value adjusted for age, sex, American Indian heritage, and genotype.
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additional populations and molecular mechanistic analyses
are required to evaluate this hypothesis more rigorously.
Very little is known regarding RNASEK except that it is
expressed in most tissues and encodes an endoribonuclease that cleaves ApU and ApG phosphodiester bonds
(26,27). Additional studies are needed to determine how
RNASEK may play a role in the development of type 2
diabetes.
In conclusion, our study identiﬁed a modest association
between the SLC16A11 variant rs75493593 and type 2 diabetes in 12,811 American Indians, where the effect on diabetes was much more pronounced in nonobese individuals.
Analysis of longitudinal measures of BMI suggests that at
least some of the difference in BMI is due to greater weight
loss in those that carry the A risk allele and develop type 2
diabetes. rs75493593 was also associated with RNASEK gene
expression, suggesting that either altered SLC16A11 protein
function, RNASEK gene expression, or both may be contributing to the phenotypic associations observed in this study.

Acknowledgments. The authors thank all of the American Indian
volunteers included in this study.
Funding. This research was supported by the Intramural Research Program of
the National Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health. The SHS was supported by cooperative agreement grants
U01-HL41642, U01-HL41652, U01-HL41654, U01-HL65520, and U01-HL65521
from the National Heart, Lung, and Blood Institute. This study utilized the
computational resources of the Biowulf system at the National Institutes of
Health, Bethesda, MD (for a description, see https://helix.nih.gov/).
The opinions expressed in this article are those of the author(s) and do not
necessarily reﬂect the views of the Indian Health Service who helped support the SHS.
Duality of Interest. No potential conﬂicts of interest relevant to this article
were reported.
Author Contributions. M.T., R.L.H., L.J.B., and C.B. contributed to the
study design, researched the data, and wrote the manuscript. A.M., S.K., P.P.,
S.C., J.E.C., J.B., H.G., S.K., R.G.N., and B.V.H. contributed data. W.C.K. contributed
to the study design and contributed data. C.B. is the guarantor of this work and,
as such, had full access to all the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis.
References
1. Williams AL, Jacobs SB, Moreno-Macías H, et al.; SIGMA Type 2 Diabetes
Consortium. Sequence variants in SLC16A11 are a common risk factor for type 2
diabetes in Mexico. Nature 2014;506:97–101
2. Hanson RL, Rong R, Kobes S, et al. The role of established type 2 diabetessusceptibility genetic variants in a high-prevalence American Indian population.
Diabetes 2015;64:2646–2657
3. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and
prevalence in Pima Indians: a 19-fold greater incidence than in Rochester,
Minnesota. Am J Epidemiol 1978;108:497–505
4. American Diabetes Association Expert Committee on the Diagnosis and
Classiﬁcation of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis
and Classiﬁcation of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
6. Knowler WC, Coresh J, Elston RC, et al.; Family Investigation of Nephropathy and Diabetes Research Group. The Family Investigation of Nephropathy and
Diabetes (FIND): design and methods. J Diabetes Complications 2005;19:1–9

Downloaded from http://diabetesjournals.org/diabetes/article-pdf/65/2/510/581340/db150571.pdf by guest on 27 October 2022

category (,25 kg/m2) and lower in the heaviest BMI category (.35 kg/m2). As analyses of diabetes incidence, by
necessity, exclude prevalent cases at baseline, the HRs
from the longitudinal analyses may not be reﬂective of
lifetime diabetes risk. However, the cross-sectional and
longitudinal results together suggest that BMI may have
a modulatory effect on the development of type 2 diabetes in individuals who carry the rs75493593 A allele. We
also detected a strong rs75493593 genotype 3 diabetes
interaction for BMI in the American Indians, where an
association between rs75493593 and BMI only occurred
in individuals with type 2 diabetes. However, the crosssectional analyses cannot determine whether individuals
were leaner before or after the onset of type 2 diabetes
(i.e., are only lean individuals at increased risk for type 2
diabetes if they carry the A allele or do individuals with the
risk allele who develop type 2 diabetes lose more weight as
a consequence of the disease?). It has previously been
shown that American Indians, like individuals in other
ethnic groups, often lose weight after they develop diabetes (25). Analysis of the SWAI individuals with longitudinal data suggests that individuals with the risk A allele
lose weight after developing type 2 diabetes. There was no
difference in BMI by genotype in individuals who had not
developed type 2 diabetes, but a nominal association (P =
0.02) between BMI and genotype was observed in individuals following onset of the disease, where individuals
carrying the diabetes risk allele had greater weight loss. It
is unclear whether the weight loss is due to a more severe
pathophysiology of diabetes or medical treatment. Nevertheless, the association between rs75493593 and weight
loss after diabetes diagnosis observed in the SWAI sample
is very modest, suggesting that there may be other genetic
or physiological reasons for the strong association between
the diabetes risk allele and lower BMI only in the individual
with diabetes. Although analysis of in vivo metabolic data
available for a subset of SWAI subjects did not provide a
conclusive explanation of the physiological link between
rs75493593 and type 2 diabetes, a modest but reproducible
effect on lipid oxidation rates was observed, which is consistent with the suggestion that SLC16A11 may be involved in lipid metabolism (1). Our genome-wide eQTL
analysis suggests that rs75493593 or a variant in high LD
may also affect expression of RNASEK, which is located
approximately 27 kb upstream of SLC16A11, where individuals carrying the type 2 diabetes risk A allele have
lower RNASEK expression levels compared with individuals homozygous for the C allele. Given these results observed in three different tissues that were biopsied from
different individuals, we propose that RNASEK expression
may be mediating, at least in part, the association between
rs75493593 and type 2 diabetes. Our mediation analyses
demonstrate that the pattern of associations is consistent
with this hypothesis; however, these results could be confounded by complex pleiotropic relationships among the
traits or LD between causal variants that independently
inﬂuence RNASEK expression and diabetes risk. Studies in

Diabetes Volume 65, February 2016

diabetes.diabetesjournals.org

519

17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. BMJ 2003;327:557–560
18. Mason CC, Hanson RL, Ossowski V, et al. Bimodal distribution of RNA
expression levels in human skeletal muscle tissue. BMC Genomics 2011;12:98
19. Göring HH, Curran JE, Johnson MP, et al. Discovery of expression QTLs
using large-scale transcriptional proﬁling in human lymphocytes. Nat Genet
2007;39:1208–1216
20. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, et al. A re-annotation
pipeline for Illumina BeadArrays: improving the interpretation of gene expression
data. Nucleic Acids Res 2010;38:e17
21. Baron RM, Kenny DA. The moderator-mediator variable distinction in social
psychological research: conceptual, strategic, and statistical considerations. J
Pers Soc Psychol 1986;51:1173–1182
22. Preacher KJ, Kelley K. Effect size measures for mediation models: quantitative strategies for communicating indirect effects. Psychol Methods 2011;16:
93–115
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol
1995;57:289–300
24. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:
1073–1081
25. Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and
after the development of type 2 diabetes. Diabetes Care 2001;24:1917–1922
26. Kiritsi MN, Fragoulis EG, Sideris DC. Essential cysteine residues for human
RNase k catalytic activity. FEBS J 2012;279:1318–1326
27. Economopoulou MA, Fragoulis EG, Sideris DC. Molecular cloning and
characterization of the human RNase kappa, an ortholog of Cc RNase. Nucleic
Acids Res 2007;35:6389–6398

Downloaded from http://diabetesjournals.org/diabetes/article-pdf/65/2/510/581340/db150571.pdf by guest on 27 October 2022

7. American Diabetes Association. Diagnosis and classiﬁcation of diabetes
mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69
8. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of
cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141–1155
9. Alberti KGMM, Zimmet PZ. Deﬁnition, diagnosis and classiﬁcation of diabetes
mellitus and its complications. Part 1: diagnosis and classiﬁcation of diabetes
mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553
10. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory
dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988–1992
11. Norman RA, Tataranni PA, Pratley R, et al. Autosomal genomic scan for loci
linked to obesity and energy metabolism in Pima Indians. Am J Hum Genet 1998;
62:659–668
12. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C. Determinants of
24-hour energy expenditure in man. Methods and results using a respiratory
chamber. J Clin Invest 1986;78:1568–1578
13. Devlin B, Bacanu SA, Roeder K. Genomic control to the extreme. Nat Genet
2004;36:1129–1130; author reply 1131
14. Tian C, Hinds DA, Shigeta R, et al. A genomewide single-nucleotidepolymorphism panel for Mexican American admixture mapping. Am J Hum Genet
2007;80:1014–1023
15. Hanis CL, Chakraborty R, Ferrell RE, Schull WJ. Individual admixture estimates: disease associations and individual risk of diabetes and gallbladder
disease among Mexican-Americans in Starr County, Texas. Am J Phys Anthropol
1986;70:433–441
16. Petitti DB. Statistical methods in meta-analysis. In Meta-Analysis, Decision
Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in
Medicine. Petitti DB, Ed. Oxford, Oxford University Press, 2000, p. 94–118

Traurig and Associates

